Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations. 1985

M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker

A new multicomponent Pseudomonas vaccine 'pyoimmunogen' has been developed. It was tested for safety and immunogenicity by immunization of volunteer donors and burned patients. Immune plasma obtained from volunteers was used for treatment of severe forms of P. aeruginosa infections. Pyoimmunogen was shown to be of low toxicity for apparently healthy humans and to induce specific antibody formation. In 16 out of 20 burned patients it had a beneficial effect on the course of the disease and the period of hospitalization was shortened. As a result of complex treatment involving the use of anti-P. aeruginosa plasma 51 out of 60 patients recovered.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
January 1982, Journal of hygiene, epidemiology, microbiology, and immunology,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
June 1985, Vaccine,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
July 1991, Vaccine,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
February 2008, Vaccine,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
January 1989, Contributions to microbiology and immunology,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
January 2020, Human vaccines & immunotherapeutics,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
May 1982, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
January 2015, Human vaccines & immunotherapeutics,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
January 1978, Archives roumaines de pathologie experimentales et de microbiologie,
M A Krokhina, and I A Grishina, and Panova YuM, and R P Terekhova, and M K Severtsova, and L S Yedvabnaya, and M Vaide, and R Varro, and V M Rusanov, and I I Kolker
December 1972, British journal of experimental pathology,
Copied contents to your clipboard!